top of page
Search

How to Develop an Ayurvedic Cannabis Product in India: Formulation, Licensing, Manufacturing and Launch

Writer: Vikram Mitra
Vikram Mitra
Oct 3
17 min read

By Delta Botanicals & Research · Last updated: 3 October 2026


This article is for general information and is not legal or medical advice. Cannabis-containing ASU products can involve central, state, drug-regulatory and excise considerations. The right pathway depends on the actual formulation, source material, intended claims and manufacturing structure. Confirm the current requirements for your specific product before acting.


Key takeaways


  • Start with the regulatory identity of the product, not the cannabinoid percentage on the pack.

  • The first decision is whether the product fits the Ayurvedic (ASU) framework at all and, if it does, whether it is classical (section 3(a)) or patent or proprietary (section 3(h)).

  • Ayurveda works with botanical drugs, preparations and multi-ingredient formulations. It does not define a medicine around a single isolated cannabinoid such as CBD.

  • Since the Ministry of Ayush order of 7 August 2024, state and UT licensing authorities license specified cannabis-containing ASU drugs only after Central Government clearance.

  • Schedule E(1) affects more than the label. It shapes medical supervision, online sale and therefore your whole distribution model.

  • A licence does not rescue a weak business model. Test MOQ, packaging, claims, channel economics and working capital before production starts.


Infographic from Delta Botanicals & Research showing 10-step Ayurvedic cannabis product pathway: Define, Build, Launch.

"I want to launch a 10% CBD oil."


It is one of the most common ways a cannabis product conversation begins, and it is usually the wrong place to start an Ayurvedic project.


When you are thinking about Ayurvedic cannabis product development, before asking which manufacturer can make the oil, which bottle to use or how much CBD to put on the front of the pack, ask something more basic:


What product are you asking the regulatory system to recognise and license?


If the product genuinely follows the Ayurvedic route, its regulatory identity comes from the botanical material, the formulation, the processing, the dosage form and the ASU category. "10% CBD oil" is a commercial description. It is not a regulatory pathway.


This guide sets out the sequence we use when we assess an Ayurvedic cannabis product project in India. If you want the history and the classical texts first, read our companion guide, Cannabis in Ayurveda: Vijaya, Classical Formulations and the Indian Regulatory Context.


A note on "hemp Ayurvedic" searches


People often search for "hemp Ayurveda formulation". In this framework the ingredient is Vijaya/Bhanga (cannabis) and the route is a licensed Ayurveda, Siddha and Unani (ASU) drug. Industrial hemp and hemp-seed foods are different routes under different rules. See hemp licence vs cannabis licence in India.



The 10-Step Pathway


Every step has a gate. Don't spend heavily on the next stage until you can clear the one before it.

#

Step

Move forward when you can say…

1

Product concept

"We can explain what the product is without relying on the word CBD."

2

Ayurvedic fit and formulation basis

"We know whether the ASU route fits, and whether the formulation is classical or proprietary."

3

Ingredient and source assessment

"Every material is identified, documented, lawfully sourced and commercially available."

4

Regulatory pathway mapping

"We know which authorities, licences, reviews and permissions may apply."

5

Manufacturer selection

"The manufacturing structure and facility fit the product."

6

Dossier and filing strategy

"The formulation, evidence, specifications, label and supporting documents are ready."

7

Testing and specifications

"We know exactly what the raw material and finished product must meet."

8

Label, claims and channel

"What we say and how we sell it match the licensed product."

9

Packaging

"The pack protects the formulation and suits its use and distribution."

10

Commercial production and launch

"We can make it repeatedly and the economics still work."


There is deliberately no "launch in 90 days" promise here. Timing depends on the product, the documents, the state, the manufacturing structure and the regulatory pathway.



Step 1: Define the Product Before the CBD Percentage


Describe the product without using the word CBD. What is the dosage form? Who is it for? What is it meant to do? Will it be practitioner-led, pharmacy-led or sold through another permitted channel? Is its identity built around an Ayurvedic formulation, or around a modern isolated cannabinoid? Those are very different projects.


Why "10% CBD oil" is the wrong starting question


Ayurveda approaches medicines through botanical drugs, preparations, processing methods and formulations. It does not define Vijaya through isolated modern compounds such as cannabidiol.


That doesn't make CBD and THC irrelevant. Modern analysis can measure cannabinoid content, and those numbers matter for characterisation, specification, quality control and regulatory assessment. But:


A cannabinoid percentage can characterise an Ayurvedic cannabis formulation. It should not define it.


The ASU framework works with botanical drugs and preparations and, within limits set by the rules, plant extracts. Exactly which extracts are permissible depends on the current rule text, so check it for your formulation. The important distinction is not "whole plant versus science". It is botanical, formulation-led medicine versus molecule-led product identity.


If your whole proposition depends on an isolated cannabinoid, a novel active or a modern clinical claim, the Ayurvedic route may not be the right one at all.



Step 2: Does the Product Fit Ayurveda, and Is It Classical or Proprietary?


Ask first: should this be an Ayurvedic medicine in the first place? If yes, the next decision is usually between a classical ASU formulation and a patent or proprietary ASU formulation. The Ministry of Ayush's 2024 order refers to both, as sections 3(a) and 3(h) of the Drugs and Cosmetics Act.


Question

Points to classical

Points to proprietary

Can you name an authoritative text and follow its formula exactly?

Yes

No

Do you want a distinctive formulation you can defend as your own?

No

Yes

Are all ingredients found in the authoritative texts?

Yes

Yes (required)

Do you want to combine ingredients in ways the texts do not?

No

Yes

Is brand differentiation or IP central to your plan?

No

Yes

Is traditional positioning your goal?

Yes

Possible

A proprietary product does not mean any ingredient can be added to an Ayurvedic formula. If someone wants to add a newly isolated cannabinoid, a novel active, or an ingredient with no basis in the ASU framework, the right response is not "let's find a manufacturer who'll make it". It is "we need to re-check the classification."


A worked example

Infographic from Delta Botanicals & Research comparing premium cannabinoid oil marketing terms with regulatory requirements.

A founder says: "I want to launch a premium cannabinoid oil in India." We wouldn't start by asking about bottle size. We'd reframe the project.


  1. Remove the marketing label. "Cannabinoid oil" doesn't tell us what the regulatory product is. Is it an Ayurvedic botanical formulation, an extract-based ASU formulation, a product built around an isolated cannabinoid, or something else?

  2. Ask what gives it its identity. If the proposition is "this contains X% isolated CBD", the Ayurvedic route may be a poor fit. If it comes from an Ayurvedic botanical formulation using recognised ingredients and processing, the conversation is different.

  3. Decide the formulation basis. If the formula comes from an authoritative text, look at the classical route. If the business wants a differentiated formulation using eligible Ayurvedic ingredients, look at the proprietary route.

  4. Only then move into development: source, permissions, manufacturer, evidence, specifications, testing, label, packaging and economics.


The same opening sentence can lead to completely different projects. You want to find that out before money goes into formulation and inventory.



Step 3: Assess Every Ingredient and Its Source


With cannabis, "which ingredient?" is not enough. Ask: which plant material, from which source, prepared how, documented how, and available at what commercial scale?

That matters because cannabis regulation in India is sensitive to plant part and to state-level controls. For Ayurvedic use, processing matters too. The classical literature describes shodhana, and modern pharmacognostic work continues to study the identity and chemistry of Vijaya leaves.


Delta's SPECS questions


We use five questions for ingredient diligence, described in full in our sourcing guide:

  • S, Source: where did the material originate?

  • P, Permission: what permits, licences or regulatory basis allow it to be cultivated, procured, held or supplied?

  • E, Extract or ingredient specification: what exactly is being bought?

  • C, Certificates and testing: what documents establish identity and quality?

  • S, Supply consistency: can the supplier reproduce the same material commercially?


A good Certificate of Analysis can't fix an unclear source, and a lawful source can't make up for an unsuitable specification. You need both.


Development material is not automatically exempt


Another common mistake is to assume prototypes sit outside regulation. Collecting, possessing, moving or processing cannabis material for development work may itself need permissions. Don't order material for a "trial batch" first and ask questions later.



Step 4: Map the Regulatory Pathway


Once you know the formulation concept and the ingredients, map every authority and dependency. This is where a product idea becomes a regulatory project.


The central-clearance order of August 2024


On 7 August 2024, the Ministry of Ayush issued an order under Section 33P of the Drugs and Cosmetics Act. It directed State and UT licensing authorities to grant licences for ASU drugs under sections 3(a) and 3(h) containing specified cannabis materials, including Bhanga/Bhang, Ganja and Charas (except seed), only after obtaining clearance from the Central Government. Existing licences and pending applications were to be sent to the Ministry for review. The order followed an inter-ministerial committee set up in April 2024 to address illegal selling of ASU drugs containing Bhang.


For a founder, the consequence is simple: don't build your launch plan around a state-level conversation alone. A cannabis-containing ASU project can involve an additional central layer. Find that out before you:


  • commit to a launch date;

  • pay large manufacturing advances;

  • order packaging;

  • commit marketing spend;

  • build inventory forecasts.


The ASU rules were amended again in July 2026


According to trade reports, the Ministry of Ayush notified the Drugs (Eleventh Amendment) Rules, 2026 as G.S.R. 657(E) around 24 July 2026. Those reports describe changes touching ASU licensing, GMP, technical-staff requirements, labelling and traceability, and the treatment of certain extract-based single-plant formulations. We have not assumed the details, and the amendment is not a blanket approval for any cannabis extract or CBD preparation. Read the Gazette text for your product, and confirm how the 2024 clearance process operates today.


One point is often misreported: licence validity itself is not a 2026 change. ASU manufacturing licences (Form 25-D) and loan licences (Form 25-E) have been perpetual since the Drugs (Fourth Amendment) Rules, 2021, subject to annual self-declarations and a valid GMP certificate.



Step 5: Choose a Manufacturing Structure, Not Just a Factory


A manufacturer's willingness to make a product doesn't prove the product fits that manufacturer's licence or your regulatory route. Ask:


  • Does the facility hold the relevant ASU manufacturing licence, and does its approved scope fit your dosage form?

  • Can it lawfully handle the proposed ingredient?

  • Does it have the testing capability the product needs?

  • Is the MOQ commercially sensible?

  • Can it support stability and packaging requirements?

  • Who owns the formula and the development data?

  • What happens if you change manufacturer?

  • Who answers regulatory queries?


Manufacturing licence vs loan licence


The Drugs Rules provide a loan licence for an applicant that has no manufacturing facility and wants to use the facilities of an existing licensee. The manufacturing licence is issued in Form 25-D and the loan licence in Form 25-E. That is why "contract manufacturing" shouldn't stay a vague commercial phrase. Before you sign anything, settle who holds the product licence, who manufactures, who controls documentation, who owns the formula, who answers the authority and who controls changes to suppliers or process.


For a full checklist, use our 12-point manufacturer audit.



Step 6: Build the Dossier and Filing Strategy


A serious product has its regulatory dossier taking shape before the first commercial batch. Typical components:


Infographic from Delta Botanicals & Research showing roles in an Ayurvedic cannabis project: client, Delta, manufacturer, authorities.

Component

Why it matters

Formulation and regulatory basis

Shows whether the product is classical, proprietary or another category

Authoritative text references, where applicable

Supports the formulation basis

Ingredient names, botanical identity and source

Connects the formulation to raw-material control

Supplier and permission documents

Establishes sourcing and traceability

Manufacturing process

Defines how the product is actually made

Raw-material and finished-product specifications

Creates the quality standard

Test methods

Shows how compliance will be demonstrated

Safety and effectiveness evidence, where applicable (Rule 158B)

Requirements vary with product category and claims

Draft label

Keeps the presentation consistent with the licensed product

Claims strategy

Stops marketing drifting beyond the regulatory basis

Dosage form and pack

Affects manufacturing, stability and use

Shelf-life and stability support

Supports commercialisation and inventory planning

Who files what. Typically the licensed manufacturer is the applicant and you supply the formulation, specifications, label and supporting documents. Where a loan-licence structure is used, responsibilities are shared in a way that depends on the arrangement. Confirm in writing who holds the licence, who files and who answers to the authority.


Evidence. Rule 158B of the Drugs Rules sets out the proof of safety and effectiveness that applies to licensing ASU drugs, with different expectations for different categories. There is no useful shortcut such as "Ayurvedic means no evidence is needed". What applies depends on the category, the ingredients and what you intend to claim. Ask early and budget for it from the start, because it shapes both cost and timing.


The portal. ASU licence applications run through the Ministry's e-Aushadhi portal. Reports indicate the portal was reset in April 2026, with fresh applications reopening on 28 April 2026. Check the current requirements on the portal before you file. Treat dossier readiness as part of project execution, not clerical work for the end.


Infographic slide from Delta Botanicals & Research titled Before You File: The Ayurvedic Cannabis Product Dossier, with checklist items and regulatory text.


Step 7: Build the Specification Before You Build the Brand


Cannabis attracts attention to one laboratory number: CBD percentage. Quality control needs to be much broader. Recent pharmacognostic work on Vijaya leaves shows the kinds of tools available for identity and characterisation: microscopy, physicochemical measurements, chromatographic techniques and cannabinoid analysis. A commercial specification should be built for your actual material and formulation. Depending on the product, it may cover:


  • botanical identity;

  • organoleptic or pharmacognostic parameters;

  • relevant pharmacopoeial parameters;

  • cannabinoid profile, where relevant;

  • chromatographic fingerprint;

  • microbial limits, contaminants, heavy metals, pesticides and residual solvents, where applicable;

  • fill weight or volume and physical characteristics;

  • stability and packaging compatibility.


A supplier's COA is useful evidence about a sample. It does not replace the finished-product manufacturer's own quality-control obligations.



Step 8: Design the Label, Claims and Channel Together

This is where product development and marketing meet. And because of Schedule E(1), this step can change your business model.


Schedule E(1) is not just a label issue

Bhanga (except seed) is listed in Schedule E(1). Under Rule 161(2) of the Drugs Rules, the container of an internal medicine made from a Schedule E(1) substance must carry the words "Caution: To be taken under medical supervision" in English and Hindi.

That has effects beyond the carton. In July 2022 the Central Consumer Protection Authority advised e-commerce platforms to sell, or facilitate the sale of, such ASU drugs only after the buyer uploads a valid prescription from a registered ASU practitioner. The advisory also points to a Ministry of Ayush public notice of 1 February 2016, which said these drugs are to be taken under medical supervision and that buying them online without medical consultation should be avoided.


Schedule E(1) can affect your channel strategy, not just your warning label.


A founder picturing a frictionless direct-to-consumer wellness oil may find that the Ayurvedic route brings practitioner supervision and online-sale conditions with it. You want to learn that during business planning, not after the online store is built.


Claims need the same discipline


Your licence, label, website, advertising, influencer content and sales material should tell the same regulatory story. A reference in a classical text doesn't automatically become a permissible modern claim. Holding an ASU manufacturing licence doesn't let a brand make any health claim it likes. Advertising of drugs is separately restricted, including under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.



Step 9: Treat Packaging as Part of Development


Don't choose packaging after the formula is final. It has to work with the product. Consider light, oxygen, moisture, compatibility with an oil or extract, closure, dose delivery, leakage, tamper evidence, transport conditions, shelf life and how people handle it.


For some cannabis-containing products, child-resistant packaging may be a sensible stewardship decision. This is not presented as a blanket legal requirement for every ASU cannabis medicine. It is a risk question: if unintended access or dosing would have serious consequences, design the pack for that. And always confirm the manufacturer can fill, seal and validate the package before you order thousands of units.



Step 10: Prove the Economics Before Commercial Production

A licence is not the finish line. A compliant product can still be a bad business. Before the first commercial batch, add up:


ingredients + manufacturing + testing + packaging + regulatory and project costs + freight and storage + marketing + distribution margins + taxes + working capital


Then test the bad case. What if you sell only 25% of the first batch? How much cash is trapped in stock? How long will the inventory last against shelf life? What happens if a supplier changes, or the manufacturer raises its MOQ? What margin is left after practitioner, distributor or marketplace economics?


Regulatory success does not guarantee commercial viability.



Where Ayurvedic Cannabis Founders Commonly Go Wrong


  • They start with the CBD percentage. The number becomes the product before anyone knows what the product legally is.

  • They pick a manufacturer before classifying the product. A willing factory is not a regulatory strategy.

  • They assume "Ayurvedic" means easier. It is a defined drug-regulatory route with its own requirements.

  • They confuse traditional use with modern claims. The two are not interchangeable.

  • They assume a supplier's COA solves sourcing. Quality documents don't replace lawful source and traceability.

  • They treat the licence as the finish line. Claims, packaging, channel restrictions, quality systems and ongoing compliance remain.

  • They ignore state-level differences. Cannabis projects can touch state excise and other state controls.

  • They promise a launch date too early. Regulatory dependencies should set the schedule, not the marketing calendar.

  • They skip the business model. A product can be technically developable and still commercially unattractive.



Should You Take the Ayurvedic Route?

It may suit you if:


  • the product has a genuine Ayurvedic formulation basis;

  • the botanical material and ingredients fit the ASU framework;

  • classical or proprietary positioning makes commercial sense;

  • practitioner or pharmacy-led channels fit your business;

  • you're comfortable working through licensed Indian manufacturing and the applicable regulatory process.


It may be a poor fit if:


  • the product is fundamentally defined by a purified or isolated cannabinoid;

  • you want to position it as an unrestricted wellness supplement;

  • a novel active is central to the formulation;

  • the intended claim depends on modern drug-development evidence;

  • your preferred business model conflicts with the supervision and distribution requirements.


Don't start with "I want to sell a 10% CBD oil" and then try to bend Ayurveda around the number. Define the product, identify the right regulatory system, then formulate for that system.



Ayurvedic Route or Phytopharmaceutical Route?


Some projects that arrive as "Ayurvedic cannabis" concepts are really closer to modern drug development. The two pathways shouldn't be confused.


Ayurvedic / ASU route

Phytopharmaceutical route

Regulatory identity

Classical or eligible patent/proprietary ASU medicine

New phytopharmaceutical drug

Foundation

The Ayurvedic textual and formulation framework

A purified and standardised botanical fraction

Who approves

State/UT licensing authority, plus applicable central clearance

CDSCO, through the new-drug pathway

Material philosophy

Botanical drugs, recognised ingredients and eligible preparations within the ASU framework

A defined, purified and standardised fraction

Evidence

Depends on the ASU category, the formulation and Rule 158B

New-drug quality, non-clinical and clinical requirements

Best suited to

Products grounded in Ayurvedic formulation logic

Evidence-led botanical drugs built around defined phytochemistry


CDSCO guidance describes a phytopharmaceutical as a purified and standardised fraction, characterised by at least four bioactive or phytochemical compounds, with clinical development requirements under the new-drug framework. A cannabis project exploring that route can also raise separate narcotics and source-material questions that deserve their own analysis.



How Delta Works


Delta Botanicals & Research is not a contract manufacturer. We work on the client's side, so our advice isn't tied to a factory we need to fill or a catalogue we need to sell. You can use us at the level the project needs.


  1. Regulatory and product pathway advisory. For founders and companies that need clarity before a larger investment. We assess the proposed product, its likely regulatory category, formulation logic, major constraints and next steps. You can carry on independently afterwards.

  2. Written pathway or scoping report. A structured roadmap your own team can implement, covering regulatory route, formulation direction, sourcing, manufacturer requirements, evidence and testing, packaging, risks and execution sequence.

  3. Product development support. Where you want us involved in development, we coordinate formulation strategy, compliant ingredient sourcing, supplier and manufacturer diligence, development samples and trials within applicable permissions, specifications and testing, packaging, label and claims review, regulatory coordination and launch preparation.

  4. Project management (PMC). We stay as your client-side project manager from concept through formulation, manufacturing, packaging and market readiness.

  5. Post-launch retainer. Ongoing support on claims and marketing compliance, manufacturer and supplier coordination, packaging changes, go-to-market execution, product strategy and future extensions.


You don't need to buy every stage. Some projects need an hour of specialist advice, some a written roadmap, some a development partner. The scope should match the project.



Frequently Asked Questions


How do I develop an Ayurvedic cannabis product in India?

Start by checking that the product genuinely fits the ASU framework. If it does, establish whether it is classical or proprietary, identify lawful ingredients and sources, map the regulatory pathway, choose the right manufacturing structure, prepare the dossier, set specifications and testing, and align label, packaging and sales channel before production.


How do I make Ayurvedic products with cannabis in India?

Through the licensed ASU route: a defined classical or proprietary formulation, lawfully sourced and processed material, a manufacturer whose licence covers your product, and the licences and clearances that apply, including central clearance for specified cannabis-containing formulations.


Do I need an AYUSH licence?

Ordinary ASU manufacturing licences are granted by the State/UT licensing authority, not by the Ministry of Ayush itself. For specified cannabis-containing formulations, the 7 August 2024 Ministry order also requires Central Government clearance before the state authority grants the licence.


Can I add CBD isolate to an Ayurvedic formulation?

Don't assume you can. Proprietary ASU medicines still operate within the recognised Ayurvedic ingredient framework. A product built around a novel or isolated cannabinoid needs a classification check before formulation begins.


Does Ayurveda use CBD?

Classical Ayurveda does not describe medicines through the modern category "CBD". It works with botanical drugs, processing and formulations. Modern cannabinoid analysis can still matter for characterisation and quality control.


Is a classical formulation easier than a proprietary one?

Not necessarily. A classical formulation has an established textual basis but little freedom to differentiate. A proprietary route offers more formulation flexibility but can bring different evidence and documentation requirements.


Can I use any Ayurvedic contract manufacturer?

No. The manufacturer's facility, licence structure, dosage form, ingredient handling and testing capability must all fit your product.


What is an ASU loan licence?

A Form 25-E loan licence lets an applicant use the manufacturing facilities of a licensed Form 25-D manufacturer. Decide the structure before you sign the manufacturing agreement.


Can I make prototype batches before I have a licence?

Don't assume development quantities are exempt. Handling or processing cannabis material can itself raise permission questions. Confirm what applies before sourcing material.


Can Ayurvedic cannabis products be sold online?

It depends on the product and the rules. For ASU medicines containing Schedule E(1) substances, the CCPA has advised e-commerce platforms to require a valid prescription from a registered practitioner before facilitating sale.


Does a Schedule E(1) product need medical supervision?

Rule 161(2) requires internal medicines containing Schedule E(1) substances to carry the caution that they are to be taken under medical supervision, in English and Hindi.


Do Ayurvedic cannabis products need clinical trials?

There is no universal answer. Rule 158B sets different safety and evidence requirements by ASU category, ingredients and claims. Classify first, then plan the evidence.


How long does approval take?

There is no responsible universal timeline. State process, product category, dossier quality, manufacturer structure and the central-clearance process all affect timing.


What does it cost to develop an Ayurvedic cannabis product?

It depends on the formulation, evidence requirements, ingredients, sourcing, testing, manufacturer, batch size, packaging and how much execution support you need. A credible budget comes from the actual pathway, not a headline number.


Can a foreign cannabis company use the Ayurvedic route?

Potentially, if the formulation genuinely fits the ASU framework and the Indian manufacturing and regulatory structure is set up correctly. Assess classification before assuming a product sold abroad can simply be imported or reproduced in India. See our market-entry guide.


What is the difference between an Ayurvedic cannabis product and a phytopharmaceutical?

An ASU product takes its regulatory identity from the Ayurvedic drug framework. A phytopharmaceutical is developed as a standardised botanical new drug, with defined phytochemistry and quality, safety and clinical evidence requirements.



Before You Appoint a Manufacturer


The most expensive mistakes usually happen before manufacturing starts: the wrong classification, ingredient, source, manufacturer, evidence assumption or channel, or a product whose economics never worked. A pathway assessment is designed to settle those questions before the project commits serious capital.


Request a Regulatory & Product Pathway Advisory


Delta Botanicals & Research can review your proposed product, current stage, formulation concept, regulatory pathway, sourcing and manufacturing needs and commercial goal before recommending the right engagement. Depending on the project, that may be a paid advisory session, a written pathway report, a defined development project, end-to-end PMC support or an ongoing post-launch retainer.

Classify first. Formulate carefully. License before launch.



Related Reading



Sources and Regulatory References

 
 
 

Comments

© 2023 by Delta Botanicals & Research Pvt Ltd

  • LinkedIn
bottom of page